Evan Marino, DO
Interventional Cardiology · Methuen, MANPI 1093000390
Payments from drug & device makers
What this record shows
Abbott accounts for 84.2% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $1,451, more than ten times the $46 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in MA, where the typical reported total is $3,030.
Across 22 payments — averaging $74.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Abiomed$99
- Novartis$33
- Opsens Inc.$23
- Cvrx, Inc.$22
- Novo Nordisk$20
- plus $62 from 4 others
What the payments were for
- Travel & lodging$87353%
- Food & beverage$77247%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $1,385 |
| Abiomed | 3 | $99 |
| Novartis | 2 | $33 |
| Opsens Inc. | 1 | $23 |
| Cvrx, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIENCE SKYPOINT$1,078
- Ultreon$105
How this compares
$1,645 in reported general payments places this provider in the 35th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 71 | $1,625 |
| Metoprolol Succinate | 71 | $826 |
| ClopidogrelClopidogrel Bisulfate | 57 | $635 |
| Carvedilol | 30 | $304 |
| Metoprolol Tartrate | 15 | $236 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $188 |
| Lisinopril | 40 | $108 |
| Amlodipine Besylate | 20 | $97 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Methuen
- Sudarshan ChatterjeeMethuen$4K
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Thomas PiemonteBurlington$330K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.